Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Anica Högner"'
Autor:
Alessandro Lorusso, Dmitry Bichev, Anica Högner, Prisca Bartels, Alexej Ballhausen, Christoph Treese, Matthias Biebl, Peter Thuss-Patience
Publikováno v:
Current Oncology, Vol 29, Iss 4, Pp 2706-2719 (2022)
The prognostic meaning of weight loss (WL) during standard treatment for operable oesophagogastric cancer is still unclear. The aim of this study is to analyse the prognostic effect of WL during perioperative chemotherapy (PC) for gastric cancer (GC)
Externí odkaz:
https://doaj.org/article/df8381edd5ec429aa489f58c10d3c84e
Autor:
Anica Högner, Markus Moehler
Publikováno v:
Current Oncology, Vol 29, Iss 3, Pp 1559-1574 (2022)
Immune checkpoint inhibition is a new standard of targeted therapy in the treatment of advanced or metastatic gastric cancer (GC) and is represented in various combinations with and without chemotherapy in every therapy line within clinical trials. I
Externí odkaz:
https://doaj.org/article/b8cda8f9c6ea469a8a988bc8ef1fb160
Autor:
Anica Högner, Peter Thuss-Patience
Publikováno v:
Pharmaceuticals, Vol 14, Iss 2, p 151 (2021)
Immune checkpoint inhibitors enrich the therapeutic landscape in oesophago-gastric carcinoma. With regard to oesophageal squamous cell carcinoma (ESCC), the selective PD-1 (programmed cell death receptor 1)-inhibitor nivolumab improves disease-free s
Externí odkaz:
https://doaj.org/article/87ca249cc52243dc832649cbc533794f
Autor:
Anica Högner, Peter Thuss-Patience
Publikováno v:
TumorDiagnostik & Therapie. 43:104-111
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e5e20a00601e2c79f5612c7862022766
https://doi.org/10.1055/a-1688-7767
https://doi.org/10.1055/a-1688-7767
Autor:
Peter Malfertheiner, Alexander Stein, Ingo Tamm, Salah-Eddin Al-Batran, PaFLO investigators, Anica Högner, Nils Homann, Axel Hinke, Kirstin Breithaupt, Jens T. Siveke, Dietrich Gläser, Peter C. Thuss-Patience, Prisca Bartels, Mario Lorenz, Arndt Vogel
Publikováno v:
International Journal of Cancer. 150:1007-1017
VEGF inhibition in gastric cancer has a proven benefit in the second line setting. Pazopanib, an oral tyrosine kinase inhibitor, selectively inhibits VEGFR-1, -2 and -3, c-kit and PDGF-R resulting in inhibition of angiogenesis. This open-label random
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf96675407fc47a29d81b1167977b1d9
https://doi.org/10.1002/ijc.33864
https://doi.org/10.1002/ijc.33864
Publikováno v:
TumorDiagnostik & Therapie. 41:588-594
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b2280e6b369e8da810d0d9e871a21ed
https://doi.org/10.1055/a-1229-7648
https://doi.org/10.1055/a-1229-7648
Autor:
Peter C. Thuss-Patience, Anica Högner, Eray Goekkurt, Michael Stahl, Albrecht Kretzschmar, Bärbel Schädlich, Thorsten Oliver Goetze, Gertraud Stocker, Peter Reichardt, Frank Kullmann, Daniel Pink, Prisca Bartels, Alexej Ballhausen, Armin Jarosch, Axel Hinke, Mascha Binder, Alexander Stein
Publikováno v:
Journal of Clinical Oncology. 40:4051-4051
4051 Background: Combination of ramucirumab and paclitaxel is a standard second line therapy in gastro-esophageal adenocarcinoma (GEAC) (RAINBOW trial, Wilke et al., 2014). We integrated the PD-L1 inhibitor avelumab into this regimen aiming for syner
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c0fefeab386578f6269fa31a53e0e7e
https://doi.org/10.1200/jco.2022.40.16_suppl.4051
https://doi.org/10.1200/jco.2022.40.16_suppl.4051
Publikováno v:
Journal of Clinical Oncology. 38:e24137-e24137
e24137 Background: Parenteral nutrition is used in cancer patients (pts) requiring intensive nutrition support due to insufficient dietary intake and consuming tumor disease. As there is no data of HPN in pts with migrant background (MB), this observ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::055955c42317ccc74c0056e499017af2
https://doi.org/10.1200/jco.2020.38.15_suppl.e24137
https://doi.org/10.1200/jco.2020.38.15_suppl.e24137
Autor:
Andreas Patzak, Inggrid Christine Wennysia, Rudolf Schubert, Pontus B. Persson, Anica Högner, Tamara Margit Jutta Pahlitzsch, En Yin Lai, Susanne Mathia, Min Ze Xu, Christian Rosenberger, Zhi Zhao Liu
Vasoconstriction plays an important role in the development of acute kidney injury in rhabdomyolysis. We hypothesized that myoglobin enhances the angiotensin II (ANG II) response in afferent arterioles by increasing superoxide and reducing nitric oxi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23a62c4e47fd679a3e9e0273cb82bc54
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/48531
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/48531
Autor:
Axel Hinke, Alexander Stein, Kirstin Breithaupt, Anica Högner, Salah-Eddin Al-Batran, Peter C. Thuss-Patience, Mario Lorenz
Publikováno v:
Journal of Clinical Oncology. 37:TPS4148-TPS4148
TPS4148 Background: Combination of ramucirumab and paclitaxel resembles the standard treatment option in second line therapy with improvement of response rate and overall survival (REGARD, RAINBOW). Response rates to PD-1/L1 blockade in gastro-esopha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a782495ffe074b8930b526cc45e501b
https://doi.org/10.1200/jco.2019.37.15_suppl.tps4148
https://doi.org/10.1200/jco.2019.37.15_suppl.tps4148